3M Innovative Properties Co. has synthesized immune response modifiers (IRMs) and their conjugates reported to be useful for the treatment of cancer and viral infections.
Much of U.S. patent law jurisprudence still revolves around subject matter eligibility, but a new decision by the Court of Appeals for the Federal Circuit revisits the question of what constitutes obviousness in patent applications. The court remanded the case between Irvine, Calif.-based Axonics Inc. and Dublin-based Medtronic plc to the Patent Trial and Appeal Board (PTAB) after determining that the PTAB judge’s understanding of obviousness is “doubly infected by error” in a decision that seems to offer some much-needed clarity where obviousness is concerned.
Novartis AG has described pyridine-3-carboxylate compounds acting as voltage-dependent L-type calcium channel subunit α-1C channel (Cav1.2) activators reported to be useful for the treatment of schizophrenia, major depression, attention deficit hyperactivity disorder, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer’s disease and Brugada syndrome.
National Institute of Pharmaceutical R&D Co. Ltd. has divulged heterocyclic compounds acting as RAC-α serine/threonine-protein kinase (AKT1; PKB α), AKT2 (PKB β) and AKT3 (PKB γ) inhibitors reported to be useful for the treatment of cancer.
Beigene Co. Ltd. has identified 3, 4-dihydroisoquinolin-1 (2h)-ones derivatives acting as stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of systemic lupus erythematosus (SLE).
Haisco Pharmaceutical Group Co. Ltd. has described bromodomain-containing protein 9 (BRD9) inhibitors or BRD9 degradation inducers reported to be useful for the treatment of cancer.
Aurigene Oncology Ltd. and Olema Pharmaceuticals Inc. have divulged fused benzoisoxazolyl compounds acting as histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) inhibitors reported to be useful for the treatment of cancer.
RSS